Ocular Hypertension Completed Phase 4 Trials for Bimatoprost (DB00905)

Also known as: Hypertension Ocular / Intraocular pressure high / Intraocular hypertension / Intraocular pressure raised / Ocular Hypertension (OHT) / Ocular Hypertension (OH) / Hypertension, Ocular / Elevated Intraocular Pressure / Intraocular pressure increased / IOP increased / Raised IOP / Ocular tension increased / Tension ocular increased / Pressure intraocular increased / Increased intraocular pressure

IndicationStatusPhase
DBCOND0074237 (Ocular Hypertension)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02017327Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DoseTreatment
NCT02061683A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionTreatment
NCT02419508SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)Treatment
NCT01298700Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionTreatment
NCT02571712Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular HypertensionTreatment
NCT02097719Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT00539526Evaluation of Hyperemia With the Use of Ocular Prostaglandin AnaloguesTreatment
NCT02020512A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionTreatment
NCT00541242Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular HypertensionTreatment
NCT00941096Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed CombinationTreatment
NCT00847483Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the USTreatment
NCT01975714Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked StudyTreatment
NCT01937312Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueTreatment
NCT01253902Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT0127168624-hour IOP-lowering Effect of 0.01% BimatoprostTreatment
NCT01263444Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyTreatment
NCT01464424Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)Treatment
NCT01664039An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®Treatment
NCT0165575824-hour Control of Intraocular Pressure (IOP) in Ocular HypertensionTreatment
NCT01594970A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)Treatment
NCT01547598Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionTreatment
NCT01525173A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionTreatment
NCT01814761A Study of Bimatoprost 0.01% in the Clinical Setting
NCT01833741A Study of LUMIGAN® RC in the Clinical SettingTreatment
NCT01881126An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT01170884Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®Treatment
NCT00440011Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%Treatment
NCT00329095An Evaluation of Use of Topical Ocular Hypotensive Medication by ComplianceDiagnostic